Nuvation Bio (NUVB) Accumulated Expenses (2020 - 2026)

Nuvation Bio (NUVB) has reported Accumulated Expenses for 7 consecutive years, with $32.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses rose 37.55% year-over-year to $32.9 million; the TTM figure through Mar 2026 stood at $32.9 million (up 37.55% YoY), while the FY2025 annual figure was $45.2 million, up 37.61% from the prior year.
• Accumulated Expenses eased to $32.9 million in Q1 2026 per NUVB's latest filing, from $45.2 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $45.2 million in Q4 2025 and bottomed at $7.1 million in Q1 2022.
• Historically, Accumulated Expenses has averaged $18.8 million across 5 years, with a median of $11.9 million in 2023.
• Annual changes were most pronounced in 2022 — Accumulated Expenses decreased 19.12% — and 2024, when it jumped 235.27%.
• Nuvation Bio's Accumulated Expenses stood at $9.8 million in 2022, then fell by 0.23% to $9.8 million in 2023, then surged by 235.27% to $32.8 million in 2024, then surged by 37.61% to $45.2 million in 2025, then decreased by 27.26% to $32.9 million in 2026.
• Business Quant data shows NUVB's Accumulated Expenses at $32.9 million in Q1 2026, $45.2 million in Q4 2025, and $32.6 million in Q3 2025.